ESMO 2023 | Novel combined ADCs in metastatic urothelial carcinoma: insights from ESMO 2023
Bradley A. McGregor, MD, Dana Farber Cancer Institute, Boston, MA, highlights the implications of the double antibody-drug conjugate (DAD) Phase I trial (NCT04724018), which assessed the safety and efficacy of sacituzumab govitecan combined with enfortumab vedotin in the treatment of metastatic urothelial carcinoma (mUC). The trial indicated that antibody-drug conjugates with different payloads and toxicities may be combined safely which may lead to novel treatment approaches in different diseases. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
